ClinicalTrials.gg

Program

latozinemab

Also written as “AL001”, “AL-001” and “Part 1 Blinded - AL001”.

Its studies are mostly in Frontotemporal Dementia · Macular Degeneration · Neurodegenerative Diseases · Amyotrophic Lateral Sclerosis · Alzheimer Disease, led by 3 companies.

Furthest: phase 3, since Apr 23, 202010 company-led studies, 3 open or runningNext primary completion: Jul 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Alector50 open or runningphase 3since Apr 23, 2020Jul 12, 2018none ahead
Alzamend Neuro31 open or runningphase 2since Apr 27, 2022Apr 27, 2022Jul 2027phase 2 · NCT07540338
Beijing Anlong Biopharmaceutical22 open or runningphase 2since Nov 25, 2024Nov 25, 2024none ahead

Also a collaborator on its studies: GlaxoSmithKline.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 12, 2018First study: phase 1 study in Frontotemporal DementiaNew to AlectorAlector · NCT03636204 · 64 enrolled · United States, Canada, United Kingdom
  2. May 14, 2019Phase 2 study in Frontotemporal DementiaAlector · NCT03987295 · 33 enrolled · United States, Canada, Germany and more
  3. Apr 23, 2020Phase 3 study in Frontotemporal DementiaAlector · NCT04374136 · 119 enrolled · United States, Argentina, Australia and more
  4. Sep 1, 2021Phase 2 study in Amyotrophic Lateral SclerosisAlector · NCT05053035 · 5 enrolled · United States
  5. Apr 27, 2022Alzamend Neuro’s first study: phase 2 study in Alzheimer DiseaseNew to Alzamend NeuroAlzamend Neuro · NCT05363293 · 65 enrolled · United States, Canada
  6. Oct 18, 2023Phase 3 study in Neurodegenerative DiseasesAlector · NCT06111014 · 17 enrolled · United States, Belgium, Canada and more
  7. Nov 25, 2024Beijing Anlong Biopharmaceutical’s first study: phase 2 study in Wet Age-related Macular Degeneration (wAMD)New to Beijing Anlong BiopharmaceuticalBeijing Anlong Biopharmaceutical · NCT06707753 · 21 enrolled · China
  8. Feb 17, 2025Phase 2 study in Wet Age-related Macular Degeneration (wAMD)Beijing Anlong Biopharmaceutical · NCT06839339 · 40 planned · China
  9. Mar 19, 2025Phase 1 study in PharmacokineticsAlzamend Neuro · NCT06921590 · 15 enrolled · United States
  10. Mar 17, 2026Phase 2 study in Bipolar I DisorderAlzamend Neuro · NCT07540338 · 20 enrolled · United States

Ahead

  1. Jul 2027Primary completion: phase 2 study in Bipolar I DisorderAlzamend Neuro · NCT07540338

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07540338Bipolar I Disorder · United States2Active, not recruitingAlzamend NeuroJul 202720
NCT06921590Pharmacokinetics · United States1CompletedAlzamend NeuroDec 15, 202515
NCT06839339Wet Age-related Macular Degeneration (wAMD) · China2Not yet recruitingBeijing Anlong BiopharmaceuticalSep 30, 202640
NCT06707753Wet Age-related Macular Degeneration (wAMD) · China2Active, not recruitingBeijing Anlong BiopharmaceuticalAug 31, 202521
NCT06111014Neurodegenerative Diseases · United States, Belgium, Canada and more3TerminatedAlectorSep 1, 202517
NCT05363293Alzheimer Disease · United States, Canada2CompletedAlzamend NeuroApr 14, 202365
NCT05053035Amyotrophic Lateral Sclerosis · United States2TerminatedAlectorOct 28, 20225
NCT04374136Frontotemporal Dementia · United States, Argentina, Australia and more3TerminatedAlectorSep 1, 2025119
NCT03987295Frontotemporal Dementia · United States, Canada, Germany and more2CompletedAlectorJun 5, 202433
NCT03636204Frontotemporal Dementia · United States, Canada, United Kingdom1CompletedAlectorDec 31, 201964

How it is read

Names in the registry

  • “AL001”, 6 entries
  • “AL-001”, 2 entries
  • “Part 1 Blinded - AL001”, 1 entry
  • “Part 2 (OLE Treatment) - AL001”, 1 entry
  • “Latozinemab”, 1 entry

Codes read as this program: AL001.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.